- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05925036
Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis (MSCPainRelief)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic pain affects approximately 50 million U.S. adults and disproportionally impacts about 20 million veterans; 1 in 3 Veterans have been diagnosed with a condition related to chronic pain. There is also a significant interaction between chronic pain, post-traumatic stress disorder (PTSD), and persistent post-concussive syndromes common to the veteran population. The opioids that are prescribed to treat chronic pain are often ineffective and are associated with a significantly increased risk of misuse, addiction, diversion, overdose, and death. Unconventional treatment options that can effectively manage pain and avoid or reduce opioid addiction in Veterans are of significant clinical importance to VA healthcare. Given the high morbidity and mortality attributable to pain therapy, not to mention the staggering medical cost, it is vital to the VA healthcare mission to explore novel strategies to treat chronic pain effectively. Chronic pancreatitis (CP) is an inflammatory disease characterized by pancreatic inflammation, fibrosis, and abdominal pain. CP subjects often suffer extreme pain, which often leads to opioid addiction. In our animal models, the investigators show a linkage between inflammatory increases in neuropeptides and pain. In humans, the investigators have more specific pain measurements to explore the link between inflammation, neuropeptides, and neuropathic pain measurement as impacted by a novel therapeutic.
Mesenchymal stromal cells (MSCs) are adult stem cells that can be harvested and expanded for therapy. MSC therapy represents a promising new intervention as increasing evidence demonstrates that MSC therapy can effectively target several injury pathways in a variety of fibroinflammatory diseases and can reduce pain while suppressing inflammation, something that most pharmacological interventions cannot accomplish.
Rationale of the study: Because MSCs are a novel therapy that my improve chronic pancreatitis pain in animal models and improve chronic pain in other human disease states, these cells are worthy of study. Specifically, the investigators propose a pilot phase 1 crossover study design in which MSCs or placebo are prospectively given to CP subjects with pain outcomes measured. This phase 1 study will inform future study designs and may lead to MSCs as a standard of care if they are safe and effective.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Magdalena N Ardelt
- Phone Number: 5015 (843) 577-5011
- Email: Magdalena.Ardelt@va.gov
Study Contact Backup
- Name: Heather N Allen
- Phone Number: 1104 (843) 608-1950
- Email: Heather.Allen6@va.gov
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401-5703
- Recruiting
- Ralph H. Johnson VA Medical Center, Charleston, SC
-
Contact:
- Hongjun N Wang, PhD
- Phone Number: 843-792-1800
- Email: hongjun.wang@va.gov
-
Principal Investigator:
- Hongjun N Wang, PhD
-
Contact:
- John T Huggins
- Phone Number: 5015 (843) 577-5011
- Email: John.Huggins@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 and 75 years old, male or female
- Definite chronic pancreatitis (stage 1-3) by M-ANNHEIM criteria
One or more of the following are required:
- Pancreatic calcifications
- Moderate or marked ductal lesions
- Marked and persistent exocrine insufficiency defined as pancreatic steatorrhea markedly reduced by enzyme supplementation
- Typical histology of an adequate histological specimen
- Patients who are diagnosed with painful CP for more than 6 months may be constant or may have been waxing and waning/remitting.
- Baseline Izbicki pain score > 50
- Stable dose of opioids for the past 30 days
Exclusion Criteria:
- Acute pancreatitis per 2012 revised Atlanta criteria within the last 30 days
- Score >7 on the Opioid Risk Tool
- Chronic pain syndromes other than pancreatitis that require daily use of opioids in the past 30 days.
- Hemoglobin of <8.0g/dL, EGFR<60 ml/min, AST or ALT >2 times upper limit of normal, Bilirubin > 1.5 mg/dl unless the subject has confirmed Gilbert syndrome., Platelets <100,000/microliter, HbA1c >10%
- Congestive Heart Failure NYHA class >1
- History of Malignancy except for in situ malignancies that have been surgically treated and basal cell skin cancers
- Evidence of active infection using current antibiotics or with Hepatitis B, C, or HIV
- Known intravenous contrast allergy causing anaphylaxis
- TWEAK score > 2 points at screening (24) (the questions below will be asked of the subjects at screening)
- Any subject who has received an investigational drug or device within 30 days before randomization or who is expected to receive an investigational drug or device during this study.
- Patients with planned endoscopic or surgical intervention, surgical resection or needle drainage of pancreatic structures in the next 6 months.
- Subjects with infected pancreatic pseudocysts or pancreatic walled-off necrotic areas at the time of consent
- Females who are pregnant or women of childbearing potential (WOCBP) and males with female partners of childbearing potential who are not willing to use adequate contraception during the study
- Breastfeeding females
- Subject unwilling to follow the protocol and assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Cohort
MSC
|
Autologous bone marrow derived MSCs
Other Names:
|
Placebo Comparator: Validation Cohort
Placebo
|
Controls
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Izbicki pain score (M6 vs. Baseline)
Time Frame: 6 month
|
Change in pain as measured by Izbicki pain scores
|
6 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in pancreatic volume measured by blinded scoring of MRI
Time Frame: Screening, 6 months and 12 months
|
Pancreas volume change
|
Screening, 6 months and 12 months
|
Change in opioid use as measured in average daily morphine equivalents.
Time Frame: Screening, 6 and 12 months
|
Average Daily morphine Equivalent.
|
Screening, 6 and 12 months
|
Change in quality of life
Time Frame: Screening, 6 and 12 months
|
Quality of life to be measured by Promise-29-v 2.1
|
Screening, 6 and 12 months
|
Change in M-Manheim Severity Index absolute score
Time Frame: Screening, 6 and 12 months
|
Severity of Index absolute scores
|
Screening, 6 and 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hongjun N Wang, PhD, Ralph H. Johnson VA Medical Center, Charleston, SC
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NURP-003-22F
- I01CX002516 (Other Grant/Funding Number: VAMC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Vastra Gotaland RegionActive, not recruitingPain, Chronic | Widespread Chronic PainSweden
-
Washington University School of MedicineCompletedHip Pain Chronic | Back Pain | Chronic Pain | Knee Pain ChronicUnited States
Clinical Trials on Mesenchymal stem cells
-
Guangzhou General Hospital of Guangzhou Military...UnknownSpinal Cord InjuryChina
-
Guangzhou General Hospital of Guangzhou Military...Guangzhou Municipal Twelfth People's Hospital; Guangdong Prevention and Treatment...Unknown
-
Guangzhou General Hospital of Guangzhou Military...UnknownParkinson's DiseaseChina
-
Hospital ZnojmoUnknown
-
National Research Center for Hematology, RussiaUnknownRelapse | Graft-versus-host DiseaseRussian Federation
-
University College, LondonUnknownTendinopathy | Achilles Tendinitis | Achilles Degeneration | Achilles Tendinitis, Right Leg | Achilles Tendon Thickening | Achilles Tendinitis, Left LegUnited Kingdom
-
Qingdao UniversityUnknownDilated CardiomyopathyChina
-
Qingdao UniversityUnknownUlcerative Colitis | Mesenchymal Stem Cells | Umbilical CordChina
-
Qingdao UniversityUnknownDiabetes Mellitus | Diabetes Mellitus, Type 1 | Mesenchymal Stem Cells | Umbilical CordChina
-
Universidad Catolica Santiago de GuayaquilMaastricht University Medical CenterUnknownOsteo Arthritis KneeEcuador